Benitec Biopharma BNTC
NASDAQ BNTC
$12.68 +0.24 (+1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Benitec Biopharma (BNTC) Accumulated Depreciation (2025)

Benitec Biopharma (BNTC) posted Accumulated Depreciation of $1.5 million for Q4 2025, up 1.84% sequentially from $1.5 million in Q2 2025.

Analysis

Benitec Biopharma (BNTC) Accumulated Depreciation (2025) Analysis & Trends

Benitec Biopharma has reported Accumulated Depreciation for 1 years, with the latest figure at $1.5 million in Q4 2025.

  • Quarterly Accumulated Depreciation changed N/A year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, changed N/A from the prior year.
  • Accumulated Depreciation rose to $1.5 million in Q4 2025 per BNTC's latest filing, from $1.5 million in the prior quarter.
  • Over five years, Accumulated Depreciation peaked at $1.5 million in Q4 2025 and troughed at $1.5 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Benitec Biopharma 588.88 Mn 588.88 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.50 Mn
Jun 30, 2025 1.47 Mn